65938-77-4

Basic information

• Product Name: 5-METHYLPYRIDINE-2-SULFONAMIDE
• Synonyms: 2-Pyridinesulfonamide,5-methyl-(9CI);2-PyridinesulfonaMide, 5-Methyl-;5-Methyl-2-pyridinesulfonamide >=97%
• CAS NO: 65938-77-4
• Molecular Formula: C₆H₈N₂O₂S
• Molecular Weight: 172.2
• Product Categories: SULFONAMIDE;Building Blocks;C6;Chemical Synthesis;Heterocyclic Building Blocks;Pyridines;Aromatics;Heterocycles;Intermediates;Sulfur & Selenium Compounds;Heterocycle-Pyridine series
• Mol File: 65938-77-4.mol

Chemical Properties

• Melting Point: 127-132 °C
• Boiling Point: 361.3°C at 760 mmHg
• Flash Point: 172.3°C
• Appearance: /
• Density: 1.346
• Vapor Pressure: 2.09E-05mmHg at 25°C
• Refractive Index: 1.564
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 9.33±0.60(Predicted)
• BRN: 389057
• CAS DataBase Reference: 5-METHYLPYRIDINE-2-SULFONAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-METHYLPYRIDINE-2-SULFONAMIDE(65938-77-4)
• EPA Substance Registry System: 5-METHYLPYRIDINE-2-SULFONAMIDE(65938-77-4)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• F: 9
• Hazardous Substances Data: 65938-77-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5-METHYLPYRIDINE-2-SULFONAMIDE is used as an intermediate in the preparation of the endothelin receptor antagonist, Clazosentan. This application is significant because Clazosentan is a medication used to treat patients with subarachnoid hemorrhage, a life-threatening condition that occurs when blood flows over the surface of the brain.
Used in Chemical Synthesis:
5-METHYLPYRIDINE-2-SULFONAMIDE is also used as a reagent in the preparation of aziridines through copper or iron-catalyzed aziridination. Aziridines are valuable compounds in organic chemistry, as they serve as building blocks for the synthesis of various pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Research and Development:
5-METHYLPYRIDINE-2-SULFONAMIDE has been utilized in the development of a copper-catalyzed aziridination protocol, which is an important advancement in the field of chemical synthesis. This protocol allows for the efficient and selective formation of aziridines, which are essential in the synthesis of complex molecules and biologically active compounds.

InChI:InChI=1/C6H8N2O2S/c1-5-2-3-6(8-4-5)11(7,9)10/h2-4H,1H3,(H2,7,9,10)

Upstream product

• 1336-21-6 ammonium hydroxide 
• 96042-30-7 4-(dicyanomethylene)-2-methyl-6-(p-dimethylaminostyryl)-4H-pyran 
• 18368-58-6 2-mercapto-5-methylpyridine 
• 3510-66-5 2-Bromo-5-methylpyridine 
• 13598-45-3 (hydroxylamino)sulfonic acid 
• 110-18-9 N,N,N,N,-tetramethylethylenediamine 
• 7446-09-5 sulfur dioxide 

Downstream Products

• 796034-71-4 5-methyl-2-[(2-phenylaziridin-1-yl)sulfonyl]pyridine 
• 1254106-80-3 C₁₉H₂₁N₃O₅S 
• 1118689-58-9 N-benzyl-5-methylpyridine-2-sulfonamide 
• 1140917-86-7 [N-(5-methyl-2-pyridinesulfonyl)imino]phenyliodinane 
• 257876-24-7 5-methyl-pyridine-2-sulfonic acid [6-chloro-2-(2-cyano-pyridine-4-yl)-5-(2-methoxy-phenoxy)-pyrimidine-4-yl]-amide 
• 796034-87-2 N-(2-phenylpropyl)(5-methyl-2-pyridine)sulfonamide 
• 960008-46-2 (RS)-S-methyl-S-(4-nitrophenyl)-N-[(5-methyl-2-pyridyl)sulphonyl]sulphimide 

Relevant articles and documents

Butyne diol derivatives

The present invention relates to novel butyne diol derivatives of the general formula I and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more compounds of the general formula I and especially their use as endothelin receptor antagonists.

Indole derivatives useful as endothelin receptor antagonists

PCT No. PCT/EP97/01882 Sec. 371 Date Oct. 5, 1998 Sec. 102(e) Date Oct. 5, 1998 PCT Filed Apr. 11, 1997 PCT Pub. No. WO97/43260 PCT Pub. Date Nov. 20, 1997Compounds of formula (I), and their pharmaceutically acceptable derivatives, wherein R1 and R2 are optional substituents and independently represent C1-6 alkyl, C2-6 alkenyl [optionally substituted by CO2H or CO2(C1-6 alkyl)], C2-6 alkynyl, halogen, C1-3 perfluoroalkyl, (CH2)mAr1, (CH2)mHet1, (CH2)mCONR7R8, (CH2)mCO2R8, O(CH2)qCO2R8, (CH2)mCOR8, (CH2)mOR8, O(CH2)pOR8, (CH2)mNR7R8, CO2(CH2)qNR7R8, (CH2)mCN, S(O)nR8, SO2NR7R8, CONH(CH2)mAr1 or CONH(CH2)mHet1; R3 represents H, C1-6, alkyl, (CH2)pNR9R10, SO2R10, SO2NR9R10, (CH2)mCOR10, C2-6 alkenyl, C2-6 alkynyl, (CH2)mCONR9R10, (CH2)mCO2R10, (CH2)pCN, (CH2)pR10 or (CH2)pOR10; R4 represents H or C1-6 alkyl; R5 represents H or OH; R6 represents phenyl optionally fused to a heterocyclic ring, the group as a whole being optionally substituted; R7-10 are fully defined herein and may independently represent Ar2 or Het2; Z represents CO2H, CONH(tetrazol-5-yl), CONHSO2O(C1-4 alkyl), CO2Ar3, CO2(C1-6 alkyl), tetrazol-5-yl, CONHSO2Ar3, CONHSO2(CH2)qAr3 or CONHSO2(C1-6alkyl); Ar1-3 independently represent phenyl, naphthyl, or an aromatic heterocycle, which groups are optionally fused and optionally substituted; and Het1 and Het2 independently represent a non-aromatic heterocycle which is optionally substituted; are useful in the treatment of restenosis, renal failure and pulmonary hypertension.